Detalhe da pesquisa
1.
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Hepatol Res;
53(1): 61-71, 2023 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36070216
2.
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
J Viral Hepat;
29(7): 551-558, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35548866
3.
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
Hepatol Res;
52(5): 462-470, 2022 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35080087
4.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hepatol Res;
52(3): 308-316, 2022 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34799975
5.
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
Hepatol Res;
52(9): 773-783, 2022 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35633504
6.
Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
J Med Virol;
93(11): 6247-6256, 2021 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34170517
7.
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Oncology;
99(8): 518-527, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33906189
8.
AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy.
BMC Cancer;
21(1): 699, 2021 Jun 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34126947
9.
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Liver Int;
41(12): 2997-3008, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34250737
10.
Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study.
BMC Gastroenterol;
21(1): 489, 2021 Dec 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34930140
11.
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study.
Hepatol Res;
51(12): 1229-1241, 2021 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34591334
12.
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
Hepatol Res;
51(8): 880-889, 2021 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33837620
13.
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
J Gastroenterol Hepatol;
36(7): 1812-1819, 2021 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33171524
14.
Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection.
J Med Virol;
92(12): 3507-3515, 2020 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32374470
15.
Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Liver Int;
40(4): 968-976, 2020 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32064740
16.
Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching.
Hepatol Res;
50(1): 75-83, 2020 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31660700
17.
Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
J Gastroenterol Hepatol;
35(2): 299-304, 2020 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31318996
18.
Combination of Resection and Ablative Treatment for Hepatocellular Carcinoma: Usefulness of Complementary Radiofrequency Ablation.
Oncology;
96(5): 242-251, 2019.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30893698
19.
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Oncology;
97(5): 277-285, 2019.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31307035
20.
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
Oncology;
97(6): 334-340, 2019.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31466068